Qynapse

Qynapse is a French medical technology company founded in 2015, emerging from the CATI consortium of neuroimaging research laboratories in Paris. The company focuses on developing AI and cloud-based software solutions aimed at enhancing the screening, diagnosis, and monitoring of central nervous system (CNS) disorders, including Alzheimer’s disease, Multiple Sclerosis, and Parkinson’s disease. Key products include QyScore®, which generates automated neuroimaging biomarkers to assist physicians in clinical decision-making, and QyPredict®, a predictive technology that aims to improve the understanding of CNS disease trajectories. Qynapse integrates proprietary AI algorithms with neuroimaging biomarkers to provide objective measures of neurodegeneration, supporting both clinical care and clinical trial applications. With a global customer base that includes healthcare providers, clinical researchers, and pharmaceutical companies, Qynapse is dedicated to improving patient outcomes and optimizing clinical trials. The company has expanded its capabilities through strategic acquisitions, including True Positive Medical Devices Inc., and holds a portfolio of 15 patents. Headquartered in France, Qynapse also has offices in the United States and Canada, fostering a collaborative work culture that encourages innovation.

• Employees 19
• Founded 2015
• Total Funding $3000000